- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1192EUR$1,250USD£1,018GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1430EUR$1,500USD£1,222GBP
- Report
- January 2024
- 175 Pages
Global
From €4767EUR$5,000USD£4,073GBP
- Report
- May 2024
- 220 Pages
Global
From €4719EUR$4,950USD£4,032GBP
- Report
- April 2024
- 136 Pages
Global
From €3717EUR$3,899USD£3,176GBP
- Report
- February 2024
- 115 Pages
Global
From €4529EUR$4,750USD£3,869GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1907EUR$2,000USD£1,629GBP
- Clinical Trials
- April 2024
- 200 Pages
Global
From €2860EUR$3,000USD£2,444GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1907EUR$2,000USD£1,629GBP
- Report
- March 2024
- 200 Pages
Global
From €3957EUR$4,150USD£3,381GBP
- Clinical Trials
- January 2024
- 257 Pages
Global
From €2384EUR$2,500USD£2,036GBP
- Report
- January 2024
- 170 Pages
Global
€4762EUR$4,995USD£4,069GBP
- Report
- May 2024
- 190 Pages
From €3217EUR$3,374USD£2,749GBP
€3574EUR$3,749USD£3,054GBP
- Report
- August 2018
- 77 Pages
Global
From €5673EUR$5,950USD£4,847GBP
- Report
- May 2024
- 134 Pages
From €6196EUR$6,499USD£5,294GBP
- Report
- January 2022
- 200 Pages
Global
From €7151EUR$7,500USD£6,109GBP
- Report
- January 2022
- 60 Pages
Global
From €3766EUR$3,950USD£3,218GBP
- Report
- January 2022
- 60 Pages
Global
From €3766EUR$3,950USD£3,218GBP
- Report
- January 2022
- 60 Pages
Global
From €3766EUR$3,950USD£3,218GBP
- Report
- January 2022
- 60 Pages
Global
From €3766EUR$3,950USD£3,218GBP
Muscular Dystrophy (MD) is a group of genetic disorders that cause progressive muscle weakness and loss of muscle mass. MD is a debilitating condition that affects millions of people worldwide. Central Nervous System (CNS) drugs are used to treat the symptoms of MD, such as muscle weakness, fatigue, and difficulty walking. These drugs can also help to slow the progression of the disease.
The Muscular Dystrophy Drug market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of MD, as well as the development of new treatments and therapies. The market is expected to continue to grow in the coming years, as more treatments become available.
Some of the major companies in the Muscular Dystrophy Drug market include Pfizer, Novartis, Merck, and Sanofi. These companies are actively developing new treatments and therapies for MD, and are expected to continue to lead the market in the future. Show Less Read more